Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib
- 23 December 2020
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 60 (3) , 283-303
Abstract
Selumetinib, a highly specific mitogen-activated protein kinase 1/2 inhibitor, is approved for children older than 2 years of age with neurofibromatosis 1 who have inoperable plexiform neurofibromas. By selectively binding to mitogen-activated protein kinase 1/2 proteins, selumetinib can arrest the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway that regulates critical cellular responses. Selumetinib has shown promising results as a single agent or in combination with conventional chemotherapy and other targeted therapies both preclinically and clinically, in multiple cancers including pediatric low-grade glioma, non-small cell lung cancer, and melanoma, among others. The pharmacokinetic profiles of selumetinib and its active metabolite N-desmethyl selumetinib have been well characterized in both adults and children. Both compounds exhibited rapid absorption and mean terminal elimination half-lives of about 7.5 h, with minimal accumulation at steady state. Three population pharmacokinetic models have been developed in adults and children, characterizing large inter- and intra-patient variabilities, and identifying significant covariates including food intake on selumetinib absorption, weight metrics, age, co-administration of cytochrome modulators, and Asian ethnicity on selumetinib apparent oral clearance. The most common side effects associated with selumetinib are dermatologic, gastrointestinal toxicities, and fatigue. Most toxicities are mild or moderate, generally tolerated and manageable. Cardiovascular and ocular toxicities remain less frequent but can be potentially more severe and require close monitoring. Overall, selumetinib exhibits a favorable safety profile and pharmacokinetic properties, with promising activity in multiple solid tumors, supporting current and further evaluation in combination with conventional chemotherapy and other targeted agents.Keywords
Funding Information
- National Cancer Institute (CA21765)
This publication has 88 references indexed in Scilit:
- MEK and the inhibitors: from bench to bedsideJournal of Hematology & Oncology, 2013
- MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumorsJournal of Clinical Investigation, 2012
- Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced MelanomaClinical Cancer Research, 2012
- A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2011
- Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein KinasesMicrobiology and Molecular Biology Reviews, 2011
- Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing programPediatric Blood & Cancer, 2010
- Response and resistance to MEK inhibition in leukaemias initiated by hyperactive RasNature, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced CancersJournal of Clinical Oncology, 2008
- Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibitionNature Structural & Molecular Biology, 2004